Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR1005 in Lewy Body Disease
NCT06537076Phase 2Recruiting
- Sponsor
- Yonsei University
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mirodenafil + rivastigmine in dementia with Lewy bodies (DLB), sponsored by Yonsei University. Started Jan 2024; status: recruiting.
02
Drugs
mirodenafil + rivastigmine
03
Conditions
dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on NCT06537076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06537076.